^
Association details:
| Biomarker: | NUP214-ABL1 fusion |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | imatinib (YD312) (c-KIT inhibitor, SCF signal transduction pathway inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia
Excerpt:
...a xenograft model of NUP214-ABL1 ALL responded to dasatinib up to 8 weeks of treatment (Figure 7D)...Together, these data indicate that EBF1-PDGFRB, BCR-JAK2, NUP214-ABL1 fusions and sequence mutations in IL7R/SH2B3 are transforming, and represent excellent candidates for therapy with currently available TKIs.
DOI:
https://dx.doi.org/10.1016%2Fj.ccr.2012.06.005
